Pegaspargase

Pegaspargase
Pegaspargase
Systematic (IUPAC) name
Pegylated E. coli L-asparagine amidohydrolase
Clinical data
AHFS/Drugs.com monograph
MedlinePlus a695031
Pregnancy cat.  ?
Legal status  ?
Identifiers
CAS number 130167-69-0 YesY
ATC code L01XX24
DrugBank BTD00079
UNII 7D96IR0PPM YesY
Chemical data
Formula C1377H2208N382O442S17 
Mol. mass 31731.9 g/mol
 N(what is this?)  (verify)

Pegaspargase (pronounced /pəˈɡæspərɡeɪz/, trade name Oncaspar) is a modified enzyme used as an antineoplastic agent. It is a form of L-asparaginase[1] which has undergone PEGylation.

It is used in the treatment of acute lymphoblastic leukemia.[2][3]

References

  1. ^ "UNM Cancer Center". http://cancer.unm.edu/drug_dictionary.aspx?id=818. Retrieved 2007-08-28. [dead link]
  2. ^ Graham ML (2003). "Pegaspargase: a review of clinical studies". Adv. Drug Deliv. Rev. 55 (10): 1293–302. doi:10.1016/S0169-409X(03)00110-8. PMID 14499708. 
  3. ^ Patel SS, Benfield P (Jun 1996). "New drug profile: pegaspargase (Polyethylene Glycol L-Asparaginase)". Clinical Immunotherapeutics 5 (6): 492–496.